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Targeting the endothelial adhesion molecules that control leukocyte trafficking into a tissue has been explored as a biological
therapy for inflammatory diseases. However, these molecules also participate in leukocyte migration for immune surveillance,
and inhibiting the physiological level of an adhesion molecule might promote infection or malignancy. We explored the concept of
targeting endothelial adhesion molecule transcription during inflammation in a human system. Intercellular adhesion molecule 1
(ICAM-1) mediates leukocyte migration across the retinal endothelium in noninfectious posterior uveitis.We observed an increase
in the transcription factor, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NF-𝜅B1), in parallel with ICAM-1, in
human retinal endothelial cells treated with tumor necrosis factor-alpha (TNF-𝛼), and identified putative binding sites for NF-𝜅B1
within the ICAM-1 regulatory region. We targeted induced NF-𝜅B1 expression in endothelial cells with small interfering (si)RNA.
Knockdown of NF-𝜅B1 significantly decreased cell surface expression of ICAM-1 protein induced by TNF-𝛼 but did not reduce
constitutive ICAM-1 expression. Consistently, NF-𝜅B1 knockdown significantly reduced leukocyte binding to cell monolayers in the
presence of TNF-𝛼 but did not impact baseline binding. Findings of this proof-of-concept study indicate that induced transcription
of endothelial adhesion molecules might be targeted therapeutically for inflammatory disease in humans.
1. Introduction
Inflammatory diseases are characterized by the accumulation
of leukocytes within one or more body tissues. The ingress of
leukocytes into a tissue from the blood stream is directed by
the adhesion molecules and chemokines that are expressed
on the vascular endothelial lining of blood vessels coursing
through that tissue [1]. By recognizing receptors on the leuko-
cyte surface, endothelial proteins coordinate the consecutive
stages of leukocyte migration: rolling; firm adhesion; spread-
ing and crawling; and diapedesis. This interaction has speci-
ficity, since endothelial adhesion molecules and chemokines
differ between vascular beds and across immunopathologies
[2, 3].
Targeting the endothelial adhesionmolecules that control
leukocyte trafficking into a tissue during inflammation has
appeal as a biological treatment for inflammatory disease [4].
However, a major challenge in the therapeutic application of
any biologic drug is the need to permit normal physiological
processes, while simultaneously targeting disease mecha-
nisms. Adhesion molecules also participate in leukocyte
migration for immune surveillance, which is the process by
which leukocytes patrol the organs of the body, to determine
the need for immune responses to threats such as tissue
injury, infectious pathogens, and tumor cells [5, 6]. Inhibiting
this physiological leukocyte activity could place the patient
with inflammatory disease at high risk of infection and/or
cancer. Indeed, clinical use of the biologic drug, natalizumab,
which targets adhesion molecule, 𝛼4-integrin (CD49D), has
been linked to the occurrence ofmelanoma, lymphoma, infec-
tions, and progressive multifocal leukoencephalopathy [7].
During inflammation, expression of endothelial adhe-
sion molecules and chemokines increases in response to
cytokines and other inflammatory mediators [8]. Induction
of these proteins depends on the molecular signal(s) and the
endothelial subpopulation, and control may be exercised at
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the level of gene transcription [9].These observations suggest
an innovative therapeutic approach: targeting the induced
expression of an endothelial adhesion molecule involved in
leukocyte migration might spare constitutive expression and
allow physiological functions to continue undisturbed.
Noninfectious posterior uveitis is a group of vision-
threatening, retina-based inflammatory diseasesmediated by
CD4+ helper T cells and myeloid cells [10]. Work from our
group and from others has demonstrated a significant role
for the immunoglobulin (Ig) superfamily member, intercel-
lular adhesion molecule 1 (ICAM-1, CD54), in interactions
between human leukocyte subsets and the retinal vascular
endothelium [11, 12]. Master inflammatory cytokine, tumor
necrosis factor-alpha (TNF-𝛼), plays an important role in the
progression of noninfectious posterior uveitis. Examination
of blood and ocular fluid samples from affected persons with
uveitis indicates high levels of TNF-𝛼 [13–16], and TNF-
𝛼 blockade is often highly effective in patients with recal-
citrant inflammation [17, 18]. In a proof-of-concept study,
we investigated the impact of transcription factor blockade
on TNF-𝛼-induced—versus constitutive—ICAM-1 expres-
sion by human retinal endothelial cells and on the interaction
between leukocytes and human retinal endothelium.
2. Materials and Methods
2.1. RNA Silencing Reagents, Cytokines, and Antibodies. Non-
targeted small interfering (si)RNA (Silencer Select Negative
Control Number 1 siRNA, catalogue number 4390843) and
siRNA designed to target nuclear factor of kappa light
polypeptide gene enhancer in B-cells 1 (NF-𝜅B1) (Silencer
Select siRNA, catalogue number 4392420) were purchased
from ThermoFisher Scientific-Ambion (Foster City, CA).
Lipofectamine RNAiMAXTransfection Reagent was sourced
from ThermoFisher Scientific-Invitrogen (Carlsbad, CA).
Human recombinant TNF-𝛼 was bought from R&D Sys-
tems (Minneapolis, MN). Mouse monoclonal anti-human
ICAM-1 antibody (clone LB-2, isotype IgG
2b,𝜅) and mouse
monoclonal IgG (clone 27-35, isotype IgG
2b,𝜅) were obtained
from BD Pharmingen (San Jose, CA). Alexa Fluor 488-
conjugated goat anti-mouse IgG (H + L) secondary anti-
body was obtained from ThermoFisher Scientific-Molecular
Probes (Eugene, OR).
2.2. Endothelial Cell and Leukocyte Lines. Our method for
generating human retinal endothelial cell lines has previously
been reported in detail [22]. In brief, endothelial cells were
isolated from human cadaver retinae by enzymatic digestion
of tissue and selection with magnetic bead-conjugated anti-
human CD31 antibody and subsequently expanded by trans-
duction with the mouse recombinant amphotropic retro-
virus, LXSN16E6E7 [23]. Work presented in our previous
publication shows that these retinal endothelial cell lines
retain their endothelial phenotype, including expression of
endothelial markers and formation of capillary-like tubes on
basementmembrane substitute [22]. Human retinal endothe-
lial cells were cultured in MCDB-131 medium (Sigma-
Aldrich, St. Louis, MO) supplemented with 10% fetal bovine
serum (FBS) (HyClone-GE Healthcare Life Sciences, Logan,
UT) and endothelial growth factors (EGM-2 SingleQuots
supplement, omitting FBS, hydrocortisone, and gentamicin;
Clonetics-Lonza,Walkersville,MD) at 37∘C and 5%CO
2
.The
THP-1 human leukocyte line (AmericanTypeCultureCollec-
tion, Manassas, VA) was maintained in suspension in RPMI-
1640 medium (ThermoFisher-GIBCO, Grand Island, NY)
supplemented with 10% FBS and 0.05mM 2-mercaptoetha-
nol.
2.3. RNA Isolation, Reverse Transcription, and Polymerase
Chain Reaction. At the conclusion of retinal endothelial cell
manipulations, culturemediumwas replacedwith BufferRLT
(Qiagen, Hilden, Germany) with 0.55mM 𝛽-mercaptoetha-
nol (Sigma-Aldrich, St. Louis, MO), and cells were frozen
at −80∘C prior to RNA extraction. Total RNA was extracted
using the RNeasy mini kit (Qiagen), according to the manu-
facturer’s instructions and including the optional on-column
DNase treatment. RNA concentration was determined by
spectrophotometry on the NanoDrop 2000 instrument
(ThermoFisher Scientific, Wilmington, DE). Reverse tran-
scription was performed using the iScript Reverse Transcrip-
tion Supermix for RT-qPCR (Bio-Rad, Hercules, CA), with
250 ng (quantitative real-time polymerase chain reaction
(PCR)) or 500 ng (PCR array) of RNA template yielding 20𝜇L
cDNA.
Quantitative real-time PCR was performed on the CFX
Connect Real-Time PCR Detection System (Bio-Rad) using
2 𝜇L of cDNA, 4 𝜇L of iQ SYBRGreen Supermix, 1.5 𝜇L each
of 20𝜇M forward and reverse primers, and 11 𝜇L of nuclease-
free water for each reaction. Amplification consisted of a pre-
cycling hold at 95∘C for 5 minutes; 40 cycles of denaturation
for 30 seconds at 95∘C; annealing for 30 seconds at 60∘C;
extension for 30 seconds at 72∘C; and a postextension hold
at 75∘C or 81∘C for 1 second. A melting curve, consisting of a
1-second hold at every 0.5∘Cbetween 70∘Cand 95∘C,was gen-
erated to confirm that a single PCR product was produced.
For each primer set, standard curves were generated with
serially diluted PCR product to confirm an efficiency of 90%
or greater. Primer sequences for all transcripts, including ref-
erence genes used for normalization, are presented in Table 1.
2.4. Polymerase Chain Reaction Array Profiling and Selection
of Transcription Factors. Confluent monolayers of human
retinal endothelial cells inmodifiedMCDB-131mediumwere
treated with TNF-𝛼 (10 ng/mL) or no cytokine (𝑛 = 5
monolayers/condition) for 60 minutes or 24 hours at 37∘C
and 5%CO
2
. Total RNAwas isolated and reverse-transcribed,
as described above. RNA integrity numberswere 9.7 or higher
by the 2100 Bioanalyzer (Agilent Technologies, Waldbronn,
Germany). Polymerase chain reaction array was performed
using the Bio-Rad PrimePCR Transcription Factor (SAB
Target List)H96Assay PCR array and following themanufac-
turer’s instructions exactly, including the use of SsoAdvanced
Universal SYBRGreen Supermix (Bio-Rad), with 2𝜇L cDNA
per reaction. Results for TNF-𝛼-treated versus control cells
were normalized to the array reference genes—GAPDH,
HPRT1, and TBP—and compared using the “Gene Study”
function of CFX Manager software (v.3.1, Bio-Rad).
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Table 1: Primer pairs and product sizes for gene transcripts studied in human retinal endothelial cells. References are provided for primer
sequences sourced from the literature. For primer pairs designed in-house, products were confirmed by sequencing.










18S rRNA Forward: 5
󸀠-GTAACCCGTTGAACCCCATT-3󸀠 151
Reverse: 5󸀠-CCATCCAATCGGTAGTAGCG-3󸀠
Cyclophilin A Forward: 5
󸀠-GACCTCTGGAGAGAAAGGATTT-3󸀠 355
Reverse: 5󸀠-GGTGATCTTCTTGCTGGTCTT-3󸀠
∗NF-𝜅B1 = nuclear factor 𝜅-light-chain-enhancer of activated B-cells 1; ICAM-1 = intercellular adhesion molecule 1; 18S rRNA = 18S ribosomal RNA.
In order to identify one candidate transcription factor for
our proof-of-concept study, we required significant increase
from baseline expression at both 60 minutes and 24 hours
(𝑝 < 0.01), plus a 1.5-fold increase in expression at one or
both time points. We interrogated the ICAM-1 regulatory
sequence for potential binding sites of transcription factors
that fulfilled these criteria.We obtained human ICAM-1 tran-
script sequence from the National Center for Biotechnology
Information “Nucleotide” database (i.e., NG 012083.1: Homo
sapiens intercellular adhesion molecule 1 (ICAM1), Ref-
SeqGene on chromosome 19), and we defined the regulatory
sequence as the 5000 bp of sequence immediately upstream
of the ICAM-1 gene transcription start site, plus the first 2
introns (3538 bp and 8452 bp). The regulatory sequence was
searched for putative binding sites of human transcription
factors using the public JASPAR database [21], with relative
profile score threshold set at 80%.
2.5. RNA Silencing. Confluent monolayers of human reti-
nal endothelial cells were transfected with 10 nM NF-𝜅B1-
targeted siRNA or nontargeted control siRNA using 1.7 𝜇L/
mL Lipofectamine RNAiMAX Reagent in modified MCDB-
131 medium, following the manufacturer’s “Forward Trans-
fection” protocol for human umbilical vein endothelial cells.
Concentrations, timing, and siRNA were determined in a
pilot study (data not shown). After 24 hours, the transfection
mixture was replaced with medium only. Monolayers treated
with NF-𝜅B1-targeted siRNA or nontargeted siRNA were
cultured for an additional 24 hours and subsequently treated
with TNF-𝛼 (10 ng/mL) or no cytokine in fresh medium for a
final 24 hours.
2.6. Retinal Endothelial ICAM-1 ELISA. The human retinal
endothelial ICAM-1 ELISA was adapted from the protocol
published by Hartwig et al. [24]. Confluent monolayers of
endothelial cells in wells of 96-well plates, transfected with
NF-𝜅B1-targeted siRNA or nontargeted control siRNA and
treated with TNF-𝛼 or no cytokine, were washed twice in
phosphate buffered saline (PBS) with 0.1% Tween-20 (PBS/
Tween-20), fixed in 1% paraformaldehyde for 30minutes, and
washed in PBS/Tween-20. Following a 30-minute block with
5% w/v skim milk in PBS (blocking solution), monolayers
were incubated with anti-human ICAM-1 antibody or mouse
monoclonal IgG at 1 𝜇g/mL in blocking solution for 45
minutes at room temperature (𝑛 = 8 monolayers/condition)
andwashed 5 timeswith PBS/Tween-20. Subsequently,mono-
layers were incubated with Alexa Fluor 488-conjugated
secondary antibody at 2.5𝜇g/mL in blocking solution for 30
minutes at room temperature and washed 5 times with PBS/
Tween-20. Finallymonolayers were treatedwith 300 nM4󸀠,6-
diamidino-2-phenylindole-dihydrochloride (DAPI) (Sigma-
Aldrich) in PBS for 5 minutes and washed 3 times in PBS. All
treatments after the fixation step were performed on a slowly
rotating orbital shaker.
Monolayer fluorescence was determined on the VICTOR
X3 Multilabel Plate Reader (Perkin Elmer, Waltham, MA)
using 485 excitation and 535 emission (Alexa Fluor 488) fil-
ters and 355 excitation and 460 emission (DAPI) filters.Mean
background fluorescence was determined from mouse IgG-
incubated wells for each condition, and this value was
subtracted from wells incubated with anti-human ICAM-1
antibody, for the matching condition. Any difference in cell
numbers between wells was accounted for by adjusting Alexa
Fluor 488 readings for DAPI readings from the same wells.
2.7. Leukocyte-Retinal Endothelial Cell Adhesion Assay. Con-
fluent monolayers of human retinal endothelial cells in wells
of 48-well plates, transfected with NF-𝜅B1-targeted siRNA
or nontargeted control siRNA and treated with TNF-𝛼 or
no cytokine, were incubated with 1 × 105 THP-1 leukocytes
suspended in modified MCDB-131 medium (𝑛 = 5 mono-
layers/condition) for 20 minutes at 37∘C and 5% CO
2
. After
removal of the THP-1 leukocyte suspensions, monolayers
were washed 4 times inmedium, rotating the plate 90 degrees
with each wash, and fixed in 10% neutral buffered formalin
for 10 minutes. The center of each well was photographed
under 100x magnification on the IX53 inverted microscope
(Olympus, Tokyo, Japan) andwith aUC50 color CCD camera
(Olympus Soft Imaging Solutions, Muenster, Germany) and
cellSens Imaging Software (v.1.8.1, Olympus). The number of




































































Figure 1: Graphs showing relative ICAM-1 transcript expression in human retinal endothelial cell monolayers, following stimulation with
TNF-𝛼 for 60minutes or 24 hours, as determined by qRT-PCR using two ICAM-1 primer pairs. Reference gene was 18S rRNA.The same result
was obtained when data were normalized to cyclophilin A reference gene. (a) shows the result obtained using ICAM-1 primer pair listed in
Table 1 that yields 282 bp product. (b) shows similar result obtained using ICAM-1 primer pair listed in Table 1 that yields 218 bp product. Bars
represent mean relative expression, with error bars showing standard error of the mean. 𝑛 = 5 monolayers/condition. Data were analyzed
by two-tailed Student’s 𝑡-test. Human retinal endothelial RNA samples used for this experiment were used for PCR array profiling study
presented in Table 2.
THP-1 leukocytes bound to the human retinal endothelial cell
monolayer in each photograph was counted and converted to
bound leukocytes/mm.
2.8. Statistical Analysis. Analysis of the PCR array is descri-
bed above. For other experiments, data for test and control
conditions were compared by two-tailed Student’s 𝑡-tests,
using GraphPad Prism v6.04 (GraphPad Software, La Jolla,
CA). In all analyses, a significant difference was defined as
one yielding a 𝑝 value less than 0.05.
3. Results and Discussion
Our proof-of-concept study explored the effect of trans-
cription factor blockade on induced—versus constitutive—
expression of an endothelial adhesion molecule in a human
uveitis model. Noninfectious posterior uveitis involves the
migration of multiple leukocyte subsets across the retinal
vascular endothelium. Intercellular adhesion molecule-1 is
a key adhesion molecule for leukocyte egress into human
retina [11, 12], and TNF-𝛼 is a master cytokine regulator of
inflammation within human retina [13–16]. We treated
human retinal endothelial cells with TNF-𝛼 and observed a
substantial increase in ICAM-1 transcript expression over 24
hours, beginning within 60 minutes of exposure (Figure 1).
This finding indicates that ICAM-1 gene transcription might
be targeted to limit induction of ICAM-1 protein expression
on retinal endothelial cells and leukocyte-retinal endothe-
lial interactions, without impacting baseline levels of these
parameters.
Expression of ICAM-1 is regulated primarily at transcrip-
tion; activation of the ICAM-1 gene regulatory sequence is
cell- and stimulus-specific [25, 26]. To identify transcription
factors involved in retinal endothelial ICAM-1 induction,
we profiled TNF-𝛼-treated human retinal endothelial cells
against cytokine-na¨ıve control cells, using a PCR array that
detected 86 well-characterized human transcription factors.
In analyzing the results of the PCR array, we focused on
transcription factors that increased significantly in parallel
with ICAM-1 and demonstrated at least 1.5-fold increase
in expression, following exposure to TNF-𝛼. The 5000 bp
of sequence immediately upstream of the ICAM-1 gene
transcription start site, plus the first 2 introns (3538 bp and
8452 bp), were searched for putative binding sites of the
candidate transcription factors.We employed JASPAR,which
is an open-access database of matrix-based nucleotide trans-
cription factor binding profiles [21].
Seven transcription factors were upregulated in human
retinal endothelial cells on exposure toTNF-𝛼 andhadpoten-
tial binding sites in the ICAM-1 regulatory sequence (Table 2).
For the purposes of proving concept, we selected NF-𝜅B1
from the group of 7 candidate transcription factors. This
selection was based on the knowledge that NF-𝜅B1 has been
linked to noninfectious posterior uveitis; for example, several
groups have reported an association between NF-𝜅B1 poly-
morphisms and Behc¸et disease, in which posterior uveitis is
classically an occlusive retinal vasculitis [27, 28].The JASPAR
analysis indicated that the ICAM-1 regulatory region included
at least 25 putative binding sites for NF-𝜅B1 (Table 3).
Despite initial enthusiasm for therapeutic manipulation
of gene expression, transcription soon came to be regarded as
“undruggable” [29]. Potential targets in transcription include
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Table 2: Transcription factors with putative binding sites within the regulatory region of intercellular adhesion molecule 1 (ICAM-1) that
increase in human retinal endothelial cells treated with tumor necrosis factor-alpha (TNF-𝛼). For the purposes of this analysis, the ICAM-1
regulatory region was defined as 5000 bp of sequence immediately upstream of the ICAM-1 gene transcription start site and the first 2 introns.
The ICAM-1 gene sequence was interrogated in the JASPAR database [21].
Transcription factor∗
Induction with TNF-𝛼
Number of binding sites60 minutes 24 hours
Fold increase 𝑝 value Fold increase 𝑝 value
ETS1 1.65 <10−5 2.15 <10−5 48
EGR1 1.36 <10−5 2.31 <10−5 268
JunB 2.95 <10−5 5.73 <10−5 148
IRF1 4.77 <10−5 5.11 <10−5 83
NF-𝜅B1 1.24 <10−3 2.75 <10−5 25
c-Rel 1.55 <10−3 1.38 <10−4 101
TGIF1 1.31 <10−4 1.70 <10−5 6
∗ETS1 = E26 transformation-specific 1; EGR1 = early growth response 1; IRF1 = interferon regulatory factor 1; NF-𝜅B1 = nuclear factor 𝜅-light-chain-enhancer
of activated B-cells 1; TGIF1 = TGFB-induced factor homeobox 1.
Table 3: Sequences and locations of NF-𝜅B1 putative binding sites
within the regulatory region of intercellular adhesion molecule 1
(ICAM-1). For the purposes of this study, the ICAM-1 regulatory
region was defined as 5000 bp of sequence immediately upstream
of the ICAM-1 gene transcription start site and the first 2 introns.
Gene sequences were obtained from the JASPAR database [21].
Sequence Location






AGGTGATTCTCCT 282 294 1
TGGGGTTTCACCA 3008 3020 −1
AGGGAGACCCCCA 3524 3536 −1
TGGGGGTCTCCCT 3524 3536 1
GGGGGACGCCCCT 3874 3886 −1
AGGGGCGTCCCCC 3874 3886 1
GAGGGATGCCCCT 4751 4763 −1
AGGGGCATCCCTC 4751 4763 1
TGGGGATTGCCGT Intron 1 (3538 bp) 12 24 1
GGGGGAATTCCAG 584 596 1
CGGGGTTTCACCA
Intron 2 (8452 bp)
1333 1345 −1
TGGTGAAACCCCG 1333 1345 1
CGGGGACTTCCCT 3433 3445 −1
AGGGAAGTCCCCG 3433 3445 1
GGGTGGATCACCA 3748 3760 −1
TGGTGATCCACCC 3748 3760 1
CGGTGAAACCCCG 6035 6047 −1
CGGGGTTTCACCG 6035 6047 1
AGGCGGATCACCT 6948 6960 −1
AGGTGATCCGCCT 6948 6960 1
AGGGAGACCCCCA 7545 7557 −1
TGGGGGTCTCCCT 7545 7557 1
AGGGGATTCTCCT 8082 8094 −1
AGGAGAATCCCCT 8082 8094 1
(1) factors that bind specific DNA sequences to activate
or inhibit RNA polymerase II-controlled transcription; (2)
coregulators that bind transcription factors to enhance or
repress activity; and (3) DNAmethylation and histone modi-
fications that direct access of transcription factors to DNA-
binding sites. However, the challenges to targeting are sig-
nificant and include the multiple gene targets of each tran-
scription factor; predominant nuclear location; and large sur-
face areas for DNA- and protein-protein interactions. Over
the past 5 years, multiple advances have begun to address
these concerns, particularly in oncology, where transcription
factor-targeted drugs are now in clinical trials [30]. DNA-
binding small molecules, polyamides, and oligonucleotide-
based decoys inhibit binding of transcription factors to pro-
moters [29]. Transcription activator-like effectors (TALEs)
and zinc finger proteins (ZFPs) provide the opportunity to
target specific DNA sequences [31].
We silencedNF-𝜅B1 transcriptwith siRNA to examine the
effect of targetingTNF-𝛼-induced ICAM-1 gene transcription
in human retinal endothelial cells. ICAM-1 exists as both
soluble and membrane-bound forms; only the membrane-
bound form is relevant to the leukocyte-retinal endothelial
cell interaction [1]. Thus, we measured the effect of NF-𝜅B1
silencing on human retinal endothelial cell surface ICAM-
1 expression, using a cellular ELISA. Knockdown of NF-
𝜅B1 significantly decreased TNF-𝛼-induced ICAM-1 protein
expression but did not reduce constitutive ICAM-1 expres-
sion (Figure 2).Wenext examined the effect ofNF-𝜅B1 silenc-
ing on leukocyte-endothelial cell interactions, by quantify-
ing THP-1 leukocyte binding to human retinal endothelial
monolayers. Knockdown of NF-𝜅B1 significantly decreased
leukocyte binding to human retinal endothelial monolayers
that were pretreated with TNF-𝛼 but did not reduce binding
to nontreated monolayers (Figure 3). Thus, NF-𝜅B1-targeted
blockade of ICAM-1 gene transcription reduces TNF-𝛼-
induced inflammatory activities of human retinal endothelial
cells that contribute to the development of noninfectious
posterior uveitis. Importantly, the blockade does not impact
baseline levels of these activities.
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(b)
Figure 2: TNF-𝛼-induced expression of cellular ICAM-1 is significantly reduced by NF-𝜅B1 silencing, but constitutive expression is not
impacted. Human retinal endothelial cell monolayers were transfected with NF-𝜅B1-targeted (NF-𝜅B1) siRNA or nontargeted (NT) control
siRNA and treated with TNF-𝛼 or no cytokine for 24 hours. Cellular ICAM-1 was fluorescently labeled by indirect immunocytochemistry;
fluorescence of endothelial monolayers was read by microplate reader and adjusted for background fluorescence and cell number. (a) Graph
showing relative level of ICAM-1 protein on the surface of endothelial cells. Bars represent mean relative level, with error bars showing
standard error of the mean. 𝑛 = 8 monolayers/condition. Data were analyzed by two-tailed Student’s 𝑡-test. ns = not significant. (b) Graph
showing relative NF-𝜅B1 transcript expression in human retinal endothelial cell monolayers that were transfected in parallel. Reference gene
was 18S rRNA. Bars represent mean relative expression, with error bars showing standard error of the mean. 𝑛 = 4 monolayers/condition.
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(b)
Figure 3: Leukocyte binding to TNF-𝛼-stimulated human retinal endothelial monolayers is significantly reduced by NF-𝜅B1 silencing, but
binding to untreatedmonolayers is not impacted. Human retinal endothelial cell monolayers were transfectedwithNF-𝜅B1-targeted (NF-𝜅B1)
siRNA or nontargeted (NT) control siRNA and treated with TNF-𝛼 or no cytokine for 24 hours. Endothelial monolayers were incubated with
THP-1 leukocytes for 20 minutes (1 × 105 cells/7.5mm2 monolayer); monolayers were photographed, and the number of leukocytes bound
per mm2 was counted. (a) Graph showing leukocytes bound to the surface of endothelial monolayers. Bars represent mean number, with
error bars showing standard error of the mean. 𝑛 = 5 monolayers/condition. Data were analyzed by two-tailed Student’s 𝑡-test. ns = not
significant. (b) Graph showing relative NF-𝜅B1 transcript expression in human retinal endothelial cell monolayers that were transfected in
parallel. Reference gene was 18S rRNA. Bars represent mean relative expression, with error bars showing standard error of the mean. 𝑛 = 4
monolayers/condition. Data were analyzed by two-tailed Student’s 𝑡-test.
4. Conclusions
Our research explores a novel treatment paradigm for nonin-
fectious posterior uveitis that also has application to human
inflammatory diseases outside the retina. We show the feasi-
bility of targeting induced—but not constitutive—expression
on the endothelium of a key adhesion molecule involved in
initiation of an inflammatory disease. Sparing constitutive
expression is expected to limit the side effects that have
complicated the use of other biologic drugs due to the roles of
targetmolecules in physiological leukocyte activity. Targeting
transcription of endothelial adhesion molecules might result
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in changes within the cell that lead to other complications.
However, current technologies permit highly specific tran-
scription blockade, and recent progress within the pharma-
ceutical field promises the possibility of local delivery to
many organs. Important tasks in translating this therapeutic
approach to the clinic are the need to define tissue- and
disease-specific adhesionmolecules for a given inflammatory
condition and consideration of individual utilization of those
adhesion molecules in leukocyte-endothelial interactions
across multiple human subjects.
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